UW-Madison scientists return to rat as biomedical research tool

May 18, 2003

MADISON - Ever a favorite of biologists because of its record as a model to understand ailments like diabetes and cancer, the lab rat lost its luster as a research tool during the past decade because it defied attempts to manipulate its genome in a prescribed way.

Now, using a novel combination of tried-and-true techniques, scientists have created the first "knockout" rats, specifically rats whose genomes have been stripped of genes that suppress breast cancer. The development, reported today (May 19) by a team of scientists from the University of Wisconsin-Madison in online editions of the journal Nature Biotechnology, promises to restore the rat to biomedical prominence.

"People have tried for more than 10 years to produce a knockout rat," says Michael N. Gould, a professor of oncology at UW-Madison's McArdle Laboratory for Cancer Research and in whose laboratory the work was conducted.

For 100 years, he explains, the rat was the model of choice for many biomedical scientists. But a decade ago, when knockout technology was first widely deployed in the mouse, the sturdy rat was dethroned. Researchers rushed to take advantage of the biomedical possibilities of an animal model whose genome could be manipulated at will, adding or subtracting genes to gain surprising insight into a host of diseases and potential treatments.

The rat, says Gould, had been "compromised by the lack of a full genetic toolbox. Over the last 10 years, the government and drug companies have invested a lot in bringing the rat up to speed. But one of the last major elusive tools for our toolbox was the ability to knock out genes."

The ability to add or subtract genes to an animal's genome lends powerful insight into the basic mechanisms of disease. New methods of disease prevention and treatment in humans, as well as a better basic understanding of development, physiology and pathology have resulted from the ability of scientists to manipulate genes in living animals.

Prior to the advent of the knockout mouse, the rat was "the model of choice for studies in physiology, pathobiology, toxicology and neurobiology," says Gould. "Anybody that gave up rats because there wasn't a knockout technology will likely want to go back" to using them.

The advantages of rats, Gould says, lie in their larger size and the plethora of disease models developed for it during the past century. "This technology gives us the opportunity to use rat models with a modern genetic approach."

For Gould, who studies the genetics that underpin breast cancer, the return of the rat spells new research opportunities because the disease manifests itself differently in the two animals.

"Tumors in the rat have a spectra of hormonal responses that is similar to the human response," he says. "It is our hope that by studying the disease more extensively in rats, we may be able to develop models for prevention and therapy."

Keeping scientists from making rat knockouts was their inability to use rat embryonic stem cells to produce rats, which could be genetically modified, as mouse stem cells are routinely used to make knockout mice. Moreover, no rat has even been produced using nuclear transfer or cloning techniques, another method by which researchers can selectively modify an animal's genome.

The development of the world's first knockout rats by Gould's lab was accomplished using techniques well know to biologists, but that had never before been used in combination with the goal of producing a knockout. Scientists have long known that it is possible to randomly disrupt an animal's genome by injecting certain chemicals. These mutations can then be passed to future generations through simple breeding. By screening the DNA of the progeny of the mutant rats using a method that can accurately pin down changes that occur to functional genes, Gould's group was able to selectively breed out two different knockout rats whose genomes each lacked a gene known to suppress breast cancer.

"None of the technologies we're using are novel," Gould says. "The novelty is how they are combined."

The technique has been patented by the Wisconsin Alumni Research Foundation.

In addition to Gould, lead co-authors of the Nature Biotechnology paper include Yunhong Zan and Jill D. Haag.
-end-
Terry Devitt, 608-262-8282, trdevitt@wisc.edu
Michael Gould 608-263-6615, gould@oncology.wisc.edu

NOTE TO EDITORS: For a high-resolution photo, visit http://www.news.wisc.edu/newsphotos/rat.html

University of Wisconsin-Madison

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.